GIPR Antagonism Emerges as a New Obesity Class: AT7687 Heads to ADA 2026 Alongside Retatrutide TRIUMPH-1 30% Data, Survodutide SYNCHRONIZE-1, and Eloralintide's Published Phase 1 — May 30, 2026 Peptide Research Update

GIPR Antagonism Steps Into the Spotlight: AT7687 Heads to ADA 2026

One of the most interesting structural debates in obesity pharmacology is whether the GIP receptor should be activated or blocked. Tirzepatide agonizes GIPR; AT7687, a first-in-class GIPR antagonist peptide from Denmark's Antag Therapeutics, does the opposite. In topline data reported January 8, 2026, a Phase 1 first-in-human study in healthy volunteers and people living with obesity found AT7687 well tolerated and suitable for once-weekly subcutaneous dosing with no titration. In an obese, insulin-resistant, pre-diabetic non-human primate study, AT7687 combined with the amylin agonist cagrilintide produced robust, sustained low-double-digit-percentage weight loss with no plateau — and notably, the additional weight loss in the combination arm was reported to be independent of appetite suppression, alongside improvements in insulin sensitivity and body composition. Antag confirmed in April 2026 that it will present AT7687 data at the ADA 86th Scientific Sessions, signaling that GIPR antagonism has matured from a theoretical counterpoint into a clinical-stage combination strategy worth tracking.

Why GIPR Antagonism Matters as a Combination Mechanism

The appeal of AT7687 is not as a standalone blockbuster but as a partner. Obesity therapy is converging on stacking complementary mechanisms — GLP-1 for appetite, amylin for satiety, glucagon for energy expenditure — and a GIPR antagonist adds metabolic benefit (insulin sensitivity, body composition) through a pathway that does not lean further on gastrointestinal tolerability. Earlier data also showed additive weight loss when AT7687 was paired with a GLP-1 agonist. That positions it as a flexible building block in future fixed-dose or co-administered regimens, in the same conceptual neighborhood as amylin agonists like eloralintide and cagrilintide. The open question remains human efficacy magnitude: the double-digit weight loss to date is from primates, not people, so Phase 2 data will be the real test.

Retatrutide TRIUMPH-1: The New High-Water Mark

On May 21, 2026, Eli Lilly reported pivotal Phase 3 TRIUMPH-1 results for retatrutide, its GLP-1/GIP/glucagon triple agonist. Topline weight loss reached 28.3% mean at 80 weeks, with 65.3% of participants on the 12 mg dose dropping below a BMI of 30, and a pre-specified blinded extension showing an average 30.3% (about 85 lbs) at 104 weeks among higher-BMI participants who continued on 12 mg. No unexpected safety signals were flagged above background rates. Retatrutide now sets the efficacy ceiling for the incretin class and reframes what 'best-in-class' means heading into ADA.

Survodutide SYNCHRONIZE-1: Glucagon/GLP-1 Dual Agonism Delivers 16.6%

Boehringer Ingelheim and Zealand Pharma reported on April 28, 2026 that the Phase 3 SYNCHRONIZE-1 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, achieved up to 16.6% mean weight loss at 76 weeks versus 3.2% on placebo, with up to 85.1% of treated adults reaching at least 5% reduction. The result places survodutide ahead of the licensed 2.4 mg semaglutide dose but below tirzepatide and the highest retatrutide doses — a reminder that the glucagon-containing dual agonists are carving out a distinct efficacy-and-metabolic-benefit niche, with full data due at ADA in June.

Eloralintide's Phase 1 Proof of Concept Reaches Peer Review

Lilly's selective amylin receptor agonist eloralintide (LY3841136) had its Phase 1 proof-of-concept study formally published in Diabetes, Obesity and Metabolism (Bhattachar et al., 2026), confirming selective amylin engagement and dose-proportional pharmacokinetics that support once-weekly dosing. This adds peer-reviewed grounding beneath the striking Phase 2 numbers already on record — up to 20.1% weight loss as monotherapy and 11.3% additional loss added to tirzepatide — and reinforces amylin agonism as a credible GLP-1-independent pillar of combination therapy, conceptually adjacent to the AT7687-plus-cagrilintide approach.

The ADA 2026 Catalyst Cluster (June 5-8, New Orleans)

The next eight days are dense with read-throughs. Full SYNCHRONIZE-1 survodutide data, retatrutide TRIUMPH-1 cardiometabolic detail, DA-1726's three accepted late-breaking posters, AT7687's GIPR-antagonist debut, and CagriSema brain-activity data are all confirmed or expected at the ADA 86th Scientific Sessions. Liver-focused readouts continue to spill over from EASL 2026, where pemvidutide's IMPACT Phase 2b 48-week MASH data (presented May 28) showed qFibrosis regression and broad cardiometabolic improvement, and DA-1726's FibroScan endpoints strengthened its dual obesity-MASH positioning. Taken together, the field is widening from 'how much weight' to 'which mechanism, which organ, and which combination' — and GIPR antagonism is now part of that conversation.

Citations

1. [1] Source
2. [2] Source
3. [3] Source
4. [4] Source
5. [5] Source
6. [6] Source